Schizophrenia Research
Volume 116, Issue 1 , Pages 44-48, January 2010

Effects of clozapine and olanzapine on cortical thickness in childhood-onset schizophrenia

Child Psychiatry Branch, NIMH, NIH, United States

Received 5 August 2009; received in revised form 19 October 2009; accepted 19 October 2009. published online 13 November 2009.

Abstract 

Background

Little is known about the effects of antipsychotic medications on gray matter (GM) in schizophrenia. Although clozapine remains the most effective antipsychotic medication in treatment-refractory cases, it is unknown whether it has a differential effect on GM development.

Methods

In an exploratory analysis, we used automated cortical thickness measurements and prospectively scanned childhood-onset schizophrenia (COS) patients who were maintained on one medication. Two atypical antipsychotic medications, clozapine (n=12, 37 scans) and olanzapine (n=12, 33 scans) were compared with respect to effects on cortical development, in contrast to GM trajectories of matched controls.

Results

There were no significant differences in the trajectories of cortical thickness between the two treatment groups with the exception of a small circumscribed area in the right prefrontal cortex, where the olanzapine group showed thicker cortex. As expected, both groups showed thinner GM compared to matched controls.

Conclusions

Although these analyses do not rule out effects of antipsychotic medications on GM development in schizophrenia, they show no differential effect between clozapine and olanzapine on GM trajectory.

Keywords: Clozapine, Cortical thickness, Childhood-onset schizophrenia

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0920-9964(09)00540-4

doi:10.1016/j.schres.2009.10.018

Schizophrenia Research
Volume 116, Issue 1 , Pages 44-48, January 2010